1. |
Kim SJ, Jung JW, Ha HY, et al. Generation of hematopoietic stem cells from human embryonic stem cells using a defined, stepwise, serum-free, and serum replacement-free monolayer culture method. Blood Res, 2017, 52(1): 37-43.
|
2. |
Gutti U, Pasupuleti SR, Sahu I, et al. Erythropoietin and thrombopoietin mimetics: natural alternatives to erythrocyte and platelet disorders. Crit Rev Oncol Hematol, 2016, 108: 175-186.
|
3. |
Tari K, Atashi A, Kaviani S, et al. Erythropoietin induces production of hepatocyte growth factor from bone marrow mesenchymal stem cells in vitro. Biologicals, 2017, 45: 15-19.
|
4. |
Shi J, Yuan B, Hu W, et al. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways. Exp Hematol, 2016, 44(11): 1044-1058.
|
5. |
Aljitawi OS, Paul S, Ganguly A, et al. Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation. Blood, 2016, 128(25): 3000-3010.
|
6. |
Rauner M, Franke K, Murray M, et al. Increased EPO levels are associated with bone loss in mice lacking PHD2 in EPO-producing cells. J Bone Miner Res, 2016, 31(10): 1877-1887.
|
7. |
Sugiyama D, Tanaka Y, Yumine A, et al. Embryonic regulation of the mouse erythropoietic niche and its clinical application. Rinsho Ketsueki, 2016, 57(7): 944-950.
|
8. |
Thériault P, Le Béhot A, ElAli A, et al. Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner. Oncotarget, 2016, 7(24): 35552-35561.
|
9. |
Lin KH, Ho YH, Chiang JC, et al. Pharmacological activation of lysophosphatidic acid receptors regulates erythropoiesis. Sci Rep, 2016, 6: 27050.
|
10. |
Shin YK, Cho SR. Exploring erythropoietin and G-CSF combination therapy in chronic stroke patients. Int J Mol Sci, 2016, 17(4): 463-469.
|
11. |
Tayebi B, Abrishami F, Alizadeh S, et al. Modulation of microRNAs expression in hematopoietic stem cells treated with sodium butyrate in inducing fetal hemoglobin expression. Artif Cells Nanomed Biotechnol, 2017, 45(1): 146-156.
|
12. |
Wege AK, Schmidt M, Ueberham E, et al. Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice: a novel approach to generate tumor cell specific human antibodies. MAbs, 2014, 6(4): 968-977.
|
13. |
Mund JA, Shannon H, Sinn AL, et al. Human proangiogenic circulating hematopoietic stem and progenitor cells promote tumor growth in an orthotopic melanoma xenograft model. Angiogenesis, 2013, 16(4): 953-962.
|
14. |
Lin S, Fu S. The correlation of hematopoietic stem cells with cancer stem cells through the regulation of stromal cells in tumor microenvironment. Med Hypotheses, 2013, 80(4): 494-497.
|
15. |
Balint JP, Gabitzsch ES, Rice A, et al. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-] -CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunol Immunother, 2015, 64(8): 977-987.
|
16. |
Bilusic M, Heery CR, Arlen PM, et al. Phase Ⅰ trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother, 2014, 63(3): 225-234.
|
17. |
Diaz CM, Chiappori A, Aurisicchio L, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med, 2013, 11: 62.
|
18. |
Geynisman DM, Zha Y, Kunnavakkam R, et al. A randomized pilot phase Ⅰ study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. J Immunother Cancer, 2013, 1: 8.
|
19. |
Park JS, Kim HS, Park HM, et al. Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model. Vaccine, 2011, 29(47): 8642-8648.
|
20. |
Japink D, Leers MP, Sosef MN, et al. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer. Anticancer Res, 2009, 29(8): 3245-3251.
|
21. |
Tuske O, Adroit G, Delferrière O, et al. BETSI, a new test bench for ion sources optimization at CEA SACLAY. Rev Sci Instrum, 2008, 79(2 Pt 2): 02B710.
|
22. |
Steinauer N, Guo C, Zhang J. Emerging roles of MTG16 in cell-fate control of hematopoietic stem cells and cancer. Stem Cells Int, 2017, 2017: 6301385.
|
23. |
Tie G, Yan J, Khair L, et al. Hypercholesterolemia increases colorectal cancer incidence by reducing production of NKT and γδ T cells from hematopoietic stem cells. Cancer Res, 2017, 77(9): 2351-2362.
|
24. |
Dhawan A, Friedrichs J, Bonin MV, et al. Breast cancer cells compete with hematopoietic stem and progenitor cells for intercellular adhesion molecule 1-mediated binding to the bone marrow microenvironment. Carcinogenesis, 2016, 37(8): 759-767.
|
25. |
Zeng C, Zhang Y, Park SC, et al. CD34(+) liver cancer stem cells were formed by fusion of hepatobiliary stem/progenitor cells with hematopoietic precursor-derived myeloid intermediates. Stem Cells Dev, 2015, 24(21): 2467-2478.
|
26. |
Li XL, Xue Y, Yang YJ, et al. Hematopoietic stem cells: cancer involvement and myeloid leukemia. Eur Rev Med Pharmacol Sci, 2015, 19(10): 1829-1836.
|